Sex and Gender-related Disparities in Clinical Characteristics and Outcomes in Heart Transplantation.

PURPOSE OF REVIEW: Limited research has been conducted on sex disparities in heart transplant (HT). The aim of this review is to analyse the available evidence on the influence of sex and gender-related determinants in the entire HT process, as well as to identify areas for further investigation. RECENT FINDINGS: Although women make up half of the population affected by heart failure and related mortality, they account for less than a third of HT recipients. Reasons for this inequality include differences in disease course, psychosocial factors, concerns about allosensitisation, and selection or referral bias in female patients. Women are more often listed for HT due to non-ischaemic cardiomyopathy and have a lower burden of cardiovascular risk factors. Although long-term prognosis appears to be similar for both sexes, there are significant disparities in post-HT morbidity and causes of mortality (noting a higher incidence of rejection in women and of malignancy and cardiac allograft vasculopathy in men). Additional research is required to gain a better understanding of the reasons behind gender disparities in eligibility and outcomes following HT. This would enable the fair allocation of resources and enhance patient care.

Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA).

AIMS: Heart failure (HF) elicits a pro-inflammatory state, which is associated with impaired clinical outcomes, but no anti-inflammatory therapies have demonstrated a clinical benefit yet. Inflammatory pathways related with the interleukin-1 axis are overactivated during episodes of acute HF. Colchicine, an anti-inflammatory drug with proven benefits in acute pericarditis and ischaemic heart disease, may target this inflammatory response. This study aims to assess the efficacy of colchicine in acute HF patients. METHODS: COLICA is a multicentre, randomized, double-blind, placebo-controlled trial enrolling 278 patients across 12 sites. Patients presenting with acute HF, clinical evidence of congestion requiring ≥40 mg of intravenous furosemide and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >900 pg/ml, are eligible for participation. Patients are enrolled irrespective of left ventricular ejection fraction, HF type (new-onset or not) and setting (hospital or outpatient clinic). Patients are randomized 1:1 within the first 24 h of presentation to either placebo or colchicine, with an initial loading dose of 2 mg followed by 0.5 mg every 12 h for 8 weeks (reduced dose if <70 kg, >75 years old, or glomerular filtration rate <50 ml/min/1.73 m2). The primary efficacy endpoint is the time-averaged proportional change in NT-proBNP concentrations from baseline to week 8. Key secondary and exploratory outcomes include symptoms, diuretic use, worsening HF episodes, related biomarkers of cardiac stress and inflammation, total and cardiovascular readmissions, mortality and safety events. CONCLUSION: COLICA will be the first randomized trial testing the efficacy and safety of colchicine for acute HF.

De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians.

Antibodies directed against donor-specific human leukocyte antigens (HLAs) can be detected de novo after heart transplantation and play a key role in long-term survival. De novo donor-specific antibodies (dnDSAs) have been associated with cardiac allograft vasculopathy, antibody-mediated rejection, and mortality. Advances in detection methods and international guideline recommendations have encouraged the adoption of screening protocols among heart transplant units. However, there is still a lack of consensus about the correct course of action after dnDSA detection. Treatment is usually started when antibody-mediated rejection is present; however, some dnDSAs appear years before graft failure is detected, and at this point, damage may be irreversible. In particular, class II, anti-HLA-DQ, complement binding, and persistent dnDSAs have been associated with worse outcomes. Growing evidence points towards a more aggressive management of dnDSA. For that purpose, better diagnostic tools are needed in order to identify subclinical graft injury. Cardiac magnetic resonance, strain techniques, or coronary physiology parameters could provide valuable information to identify patients at risk. Treatment of dnDSA usually involves plasmapheresis, intravenous immunoglobulin, immunoadsorption, and ritxumab, but the benefit of these therapies is still controversial. Future efforts should focus on establishing effective treatment protocols in order to improve long-term survival of heart transplant recipients.

Optimization of acrylic-styrene latex-based biofilms as a platform for biological indoor air treatment.

Biotechnologies have emerged as a promising solution for indoor air purification with the potential to overcome the inherent limitations of indoor air treatment. These limitations include the low concentrations and variability of pollutants and mass-transfer problems caused by pollutant hydrophobicity. A new latex-based biocoating was herein optimized for the abatement of the volatile organic compounds (VOCs) toluene, trichloroethylene, n-hexane, and α-pinene using acclimated activated sludge dominated by members of the phylum Patescibacteria. The influence of the water content, the presence of water absorbing compounds, the latex pretreatment, the biomass concentration, and the pollutant load was tested on VOC removal efficiency (RE) by varying the formulation of the mixtures. Overall, hexane and trichloroethylene removal was low (<30%), while high REs (>90%) were consistently recorded for toluene and pinene. The assays demonstrated the benefits of operating at high water content in the biocoating, either by including mineral medium or water absorbing compounds in the latex-biomass mixtures. The performance of the latex-based biocoating was likely limited by VOC mass-transfer rather than by biomass concentration in the biocoating. The latex-based biocoating supported a superior toluene and pinene removal than biomass in suspension when VOC loading rate was increased by a factor of 4.

Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review.

Introduction COVID-19 disease has caused a global health and economic crisis. The introduction of the different COVID-19 vaccines has resulted in a significant decrease in the morbidity and mortality associated with this disease. Adverse effects have been reported, including cardiological ones such as myocarditis or pericarditis after administration. Likewise, tyrosine kinase inhibitor drugs such as osimertinib used in lung cancer patients with epidermal growth factor receptor (EGFR) mutation are associated with heart failure or prolongation of the QT interval. Case report 62-year-old woman diagnosed in September 2019 of lung adenocarcinoma stage IV with bilateral lung and lymph node involvement, carrier of an EGFR mutation (Ex19Del) on treatment with osimertinib. She attended emergency department for fever and hypotension 24 h after administration of the third dose of Moderna® COVID-19 vaccine in the context of acute myocarditis with evidence of severe left ventricular (LV) dysfunction in cardiogenic shock. She required vasoactive support, non-invasive mechanical ventilation, corticotherapy, immunoglobulins and subsequent ventricular support with Impella, with improvement of the clinical picture after 3 days. Cardiac magnetic resonance imaging (MRI) showed evidence of global myocardial oedema compatible with acute myocarditis. Coronary CT showed a lesion in the anterior descending coronary artery requiring revascularization. A few days later, she presented febrile symptoms with isolation of Staphylococcus aureus in the central line catheter and antibiotherapy with cloxacillin was started, with subsequent resolution of the infectious symptoms. Conclusion This is an exceptional and controversial case of fulminant myocarditis probably related to the Modern COVID-19 vaccine in a patient diagnosed with metastatic lung adenocarcinoma on treatment with osimertinib. An increasing number of cases of myocarditis and pericarditis have been reported following vaccination with COVID-19 mRNA vaccines. In addition, retrospective data have shown an increased risk of QT prolongation and heart failure in patients treated with tyrosine kinase inhibitors. Hence, the need for close monitoring of cardiac function during treatment of these patients. Future studies will be necessary to evaluate unknown adverse reactions of these vaccines and their possible interaction with other antineoplastic drugs.

Echocardiographic Prediction of Successful Weaning From Venoarterial Extracorporeal Membrane Oxygenation.

BACKGROUND: Weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) support fails in 30% to 70% of patients. OBJECTIVE: To explore the utility of echocardiographic parameters in predicting successful disconnection from VA-ECMO. METHODS: Patients receiving VA-ECMO in a referral hospital were included. The relationships between echocardiographic parameters during the weaning trial and weaning success (survival > 24 hours after VA-ECMO explant and no death from cardiogenic shock, heart failure, or cardiac arrest during the hospital stay) and survival were evaluated. RESULTS: Of 85 patients included, 61% had successful weaning. Parameters significantly related to weaning success were higher left ventricular ejection fraction (LVEF; 40% in patients with weaning success vs 30% in patients with weaning failure, P = .01), left ventricular outflow tract velocity time integral (15 cm vs 11 cm, P = .01), aortic valve opening in every cycle (98% vs 91% of patients, P = .01), and normal qualitative right ventricular function (60% vs 42% of patients, P = .02). The LVEF remained as an independent predictor of weaning success (hazard ratio, 0.938; 95% CI, 0.888-0.991; P = .02). An LVEF >33.4% was the optimal cutoff value to discriminate patients with successful weaning (area under the curve, 0.808; sensitivity, 93%; specificity, 72%) and was related to higher survival at discharge (60% vs 20%, P < .001). CONCLUSION: Among weaning trial echocardiographic parameters, LVEF was the only independent predictor of successful VA-ECMO weaning. An LVEF >33.4% was the optimal cutoff value to discriminate patients with successful weaning and was related to final survival.

A state-of-the-art review on indoor air pollution and strategies for indoor air pollution control.

Indoor air pollution has traditionally received less attention than outdoors pollution despite indoors pollutant levels are typically twice higher, and people spend 80-90% of their life in increasing air-tight buildings. More than 5 million people die every year prematurely from illnesses attributable to poor indoor air quality, which also causes multi-millionaire losses due to reduced employee's productivity, material damages and increased health system expenses. Indoor air pollutants include particulate matter, biological pollutants and over 400 different chemical organic and inorganic compounds, whose concentrations are governed by several outdoor and indoor factors. Prevention of pollutant is not always technically feasible, so the implementation of cost-effective active abatement units is required. Up to date no single physical-chemical technology is capable of coping with all indoor air pollutants in a cost-effective manner. This problem requires the use of sequential technology configurations at the expenses of superior capital and operating costs. In addition, the performance of conventional physical-chemical technologies is still limited by the low concentrations, the diversity and the variability of pollutants in indoor environments. In this context, biotechnologies have emerged as a cost-effective and sustainable platform capable of coping with these limitations based on the biocatalytic action of plants, bacteria, fungi and microalgae. Indeed, biological-based purification systems can improve the energy efficiency of buildings, while providing additional aesthetic and psychological benefits. This review critically assessed the state-of-the-art of the indoor air pollution problem and prevention strategies, along with the recent advances in physical-chemical and biological technologies for indoor pollutants abatement.

Aneurysmal bone cyst of the mandible: case presentation and review of the literature.

The aneurysmatic osseus cyst is a very infrequent bone lesion which in some occasions can be found at the craniofacial skeleton. Among all the cystic lesions that can be found at the mandible or the maxilla it is very rare. On the other side it is at the same time very interesting in terms of its differential diagnose with other types of maxillary bone lesions We present the case of a Caucasian male with an aneurysmatic cyst located at the right angle of the mandible and a review of the literature concerning the case. We have focused on the differential diagnose, mainly with the malignancies that can be found at this location. We also comment the therapeutic options classically described for these kind of pathologies. In our patient, the surgical excision allowed a complete removal of the lesion and a posterior bone healing which made possible a implant-supported rehabilitation of the edentulous segment.

¿Cuál es su diagnóstico? / What would your diagnosis be?

No disponible

Aneurysmal bone cyst of the mandible: case presentation and review of the literature

El quiste óseo aneurismático es una lesión ósea infrecuente que raramente se localiza a nivel del esqueleto craneofacial. Es una lesión de naturaleza benigna pero de comportamiento localmente agresivo. Del conjunto de lesiones quísticas de los maxilares, constituye una variedad muy poco frecuente, que presenta sin embargo características diferenciales, respecto a otro tipo de patologías con carácter de malignidad. Presentamos un caso clínico de un varón caucásico que presentaba dicha lesión a nivel mandibular y revisamos la literatura, centrándonos en el diagnóstico diferencial con lesiones neoplásicas como el ameloblastoma o el tumor de células gigantes. Así mismo, comentamos las diferentes posibilidades terapéuticas clásicamente descritas para el tratamiento de este tipo de patologías. En el caso que nos ocupa, el tratamiento fue quirúrgico, con cureteado exhaustivo de la lesión. Dicho tratamiento consiguió una extirpación completa y una posterior regeneración ósea local, que ha permitido una rehabilitación implantosoportada del segmento dentario sobre el que asentaba la lesión inicial

The aneurysmatic osseus cyst is a very infrequent bone lesion which in some occasions can be found at the craneofacial skeleton. Among all the cystic lesions that can be found at the mandible or the maxilla it is very rare. On the other side it is at the same time very interesting in terms of its differential diagnose with other types of maxillary bone lesions We present the case of a Caucasian male with an aneurysmatic cyst located at the right angle of the mandible and a review of the literature concerning the case. We have focused on the differential diagnose, mainly with the malignancies that can be found at this location. We also comment the therapeutic options clasically described for these kind of pathologies. In our patient, the surgical excision allowed a complete removal of the lesion and a posterior bone healing which made possible a implant-supported rehabilitation of the edentulous segment